Renal Mass and Localized Renal Cancer: Active Surveillance and Follow-up After Intervention

Posted by Steven C. Campbell, MD, PhD | Oct 2021

Steven C. Campbell, MD, PhD, presented “Renal Mass and Localized Renal Cancer: Active Surveillance and Follow-up After Intervention” for the Grand Rounds in Urology audience in October 2021.

How to cite: Campbell, Steven C. “Renal Mass and Localized Renal Cancer: Active Surveillance and Follow-up After Intervention.” October 2021. Accessed Apr 2024. https://grandroundsinurology.com/renal-mass-and-localized-renal-cancer-active-surveillance-and-follow-up-after-intervention/

Renal Mass and Localized Renal Cancer: Active Surveillance and Follow-up After Intervention

In part 2 of a 2-part series, Steven C. Campbell, MD, PhD, Professor of Surgery, Associate Director of Graduate Medical Education, Program Director and Vice Chair of Urology, and Eric A. Klein Chair for Urologic Oncology and Education at the Cleveland Clinic’s Glickman Urological and Kidney Institute, presents significant 2021 updates to the American Urological Association (AUA) guidelines on localized renal cancer, focusing on active surveillance (AS) and follow-up. Dr. Campbell, who served as Chair of the AUA Guidelines Panel for Management of Localized Kidney Cancer, begins by looking at the major revisions made to the AS guidelines, particularly with regard to specifications on which patients really should be considered for AS, the intensity of surveillance in different settings, and the role of renal mass biopsy. He then considers the revised guidance around follow-up after intervention. Dr. Campbell explains the general principles behind follow-up, highlighting the need to discuss implications of stage, grade, and histology including risks of recurrence and possible sequelae of treatment, as well as the importance of performing periodic imaging, lab studies, and medical histories in patients with treated malignant renal masses. He also covers what to do if surveillance suggests metastases or local recurrence. Dr. Campbell concludes by discussing risk-based protocols and follow-up guidelines based on risk categories and prior treatment.

For more from Dr. Campbell, check out Part 1 of his series on the updated guidelines for renal mass and localized renal cancer.

About The Author

Steven C. Campbell, MD, PhD

Steven C. Campbell, MD, PhD, is Professor of Surgery, Associate Director of Graduate Medical Education, Program Director and Vice Chair of Urology, and Eric A. Klein Chair for Urologic Oncology and Education at the Cleveland Clinic’s Glickman Urological and Kidney Institute. Dr. Campbell obtained BS, MD and PhD degrees at the University of Chicago and then completed a urology residency at the Cleveland Clinic, followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center. Dr. Campbell’s primary interests have included renal cell carcinoma, bladder cancer, tumor angiogenesis, and urology residency training. His background also includes American Foundation for Urological Diseases (AFUD) and Kimmel Research Scholarship Awards. He has served as Chair of the Exam Committee for the Society of Urologic Oncology and President for the Society of Pelvic Surgeons. Dr. Campbell was Chair for the AUA Guidelines Panel for Management of Localized Kidney Cancer (2017 and 2021), and was Co-Chair for the previous iteration of this in 2009. Dr. Campbell was Co-Editor of Renal Cell Carcinoma (BC Decker, 2009) and Editor of Renal Cell Carcinoma: Clinical Management (Humana Press, 2013) and 100 Questions and Answers about Kidney Cancer (Jones and Bartlett, 2008, 2012, 2015, 2018, and 2021). Dr. Campbell has also authored or co-authored “Malignant Renal Tumors” for Campbell/Walsh Urology for the past 5 editions (2000, 2005, 2010, 2015, and 2018). Over the past decade, Dr. Campbell’s academic work has focused on the role of partial nephrectomy and radical nephrectomy in the management of renal cell carcinoma, the determinants of functional recovery after PN, the survival implications of differences in renal function after renal cancer surgery, the use of neoadjuvant TKIs to enable PN and optimize functional outcomes, and the functional implications of tumor enucleation. In 2019, Dr. Campbell received an AUA Distinguished Contribution Award for sentinel research in the field of urologic oncology, particularly in the area of renal neoplasia, and in 2020 he received the Andrew C. Novick Award from the International Kidney Cancer Association.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat